Andrew Cittadine - 30 Jun 2026 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Chief Operating Officer
Issuer ticker: MNPR
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 19:37:33 UTC
Prior SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Andrew Cittadine filed Form 4 for Monopar Therapeutics (MNPR) on 02 Jul 2026.

Key facts

This page summarizes Andrew Cittadine's Form 4 filing for Monopar Therapeutics (MNPR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 19:37.

Change

Previous filing in this sequence was filed on 02 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001863624 Primary reporting owner

Cittadine Andrew

Relationship: Chief Operating Officer
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,254
Change %: +10%
Price
Shares after: 57,923
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Tax liability

Transaction value
Shares: -2,309
Change %: -4%
Price: $92.59^*
Shares after: 55,614
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -5,254
Change %: -12%
Price: $0.000000^*
Shares after: 39,499
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,254
Exercise price
Footnotes: F1, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents shares acquired on vesting and settlement of restricted stock units.

Footnote F2

Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

Footnote F3

On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

Footnote F4

On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

Footnote F5

On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.